compounded tirzepatide vs non compounded Zepbound vs. Compounded Tirzepatide | KEWW Primary

Brazils approval of EMSs Ozivy gives the country an early role in post-patent semaglutide competition, opening a synthetic follow-on route that could reshape pricing, access and Novo Nordisks dominance.

As states cut Medicaid coverage for GLP-1 drugs, access to obesity treatment is increasingly tied to incomeraising questions for both Medicaid and Medicare.

Yesterday, the World Health Organization published a guideline in JAMA on the use and indications of #GLP-1 therapies for the management of #obesity in adults

Is this a necessary step for patient safety, or will it create a new barrier to access for those who have relied on these alternatives